You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 10, October 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (6)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurogenetics
 •Ophthalmology
 •Ophthalmological Disorders, Other
 •Pediatrics
 •Congenital Malformations
 •Genetic Disorders
 •Genetics, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

POMGnT1 Mutations in Congenital Muscular Dystrophy

Genotype-Phenotype Correlation and Expanded Clinical Spectrum

Roberta Biancheri, MD; Enrico Bertini, MD; Antonio Falace, BSc; Marina Pedemonte, MD; Andrea Rossi, MD; Adele D’Amico, MD; Sara Scapolan, MD; Laura Bergamino, MD; Stefania Petrini, PhD; Denise Cassandrini, PhD; Paolo Broda, ST; Mario Manfredi, MD; Federico Zara, PhD; Filippo M. Santorelli, MD; Carlo Minetti, MD; Claudio Bruno, MD

Arch Neurol. 2006;63:1491-1495.

Background  Muscle-eye-brain disease is a congenital muscular dystrophy with eye and brain involvement due to POMGnT1 mutations.

Objective  To describe the clinical and molecular features of 3 Italian patients with POMGnT1 mutations.

Design  Case reports.

Patients  One patient had muscle and brain abnormalities without eye involvement. Two patients had a classic muscle-eye-brain disease phenotype with different levels of clinical severity.

Results  Brain magnetic resonance imaging showed cortical malformation and posterior fossa involvement. Immunofluorescence for glycosylated {alpha}-dystroglycan performed on muscle biopsy specimens demonstrated an absent signal in 1 patient and reduced staining in 2 patients. Molecular analysis identified 5 mutations, 2 of which are novel.

Conclusion  This article adds to what is known about the genotype-phenotype correlation and expands our awareness of the clinical spectrum associated with POMGnT1 mutations.


Author Affiliations: Muscular and Neurodegenerative Disease Unit, Department of Neuroscience and Rehabilitation, University of Genova (Drs Biancheri, Pedemonte, Scapolan, Bergamino, Cassandrini, Zara, Minetti, and Bruno and Messers Falace and Broda), and Neuroradiology Unit, Giannina Gaslini Institute (Dr Rossi), Genova; Unit of Molecular Medicine, Department of Laboratory Medicine, Bambino Gesù Children's Research Hospital (Drs Bertini, D’Amico, Petrini, and Santorelli), and Department of Neurological Sciences, University of Rome "La Sapienza" (Dr Manfredi), Rome; and Istituto di Ricovero e Cura a Carattere Scientifico NEUROMED, Pozzilli, Isernia (Dr Manfredi); Italy.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Congenital muscular dystrophies with defective glycosylation of dystroglycan: A population study
Mercuri et al.
Neurology 2009;72:1802-1809.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.